In the Claims

Claims 53 and 66 are cancelled.

Applicant submits herewith a new complete claim set.

- 1. (Original) A method of inhibiting angiogenesis in a subject in need of such treatment comprising administering to the subject at least one antiangiogenic nucleic acid molecule in an amount effective to inhibit angiogenesis in the subject.
- 2. (Original) The method of claim 1, wherein the at least one antiangiogenic nucleic acid molecule comprises at least one sequence set forth as SEQ ID NOs: 1-1093.
- 3. (Original) The method of claim 1, wherein two or more antiangiogenic nucleic acid molecules are administered.
- 4. (Original) The method of claim 1, further comprising administering to the subject at least one non-nucleic acid angiogenesis inhibitor molecule.
- 5. (Original) The method of claim 1, wherein the angiogenesis is associated with a condition selected from the group consisting of a solid tumor growth, a tumor metastasis, and a precancerous lesion.
- 6. (Original) The method of claim 1, wherein the nucleic acid is a CpG nucleic acid having an unmethylated CpG motif.

 BEST AVAILABLE COPY
- 7. (Original) The method of claim 1, wherein the nucleic acid is a T-rich nucleic acid.
- 8. (Original) The method of claim 1, wherein the nucleic acid is a poly G nucleic acid.
 - 9. (Original) The method of claim 1, wherein the nucleic acid is isolated.

- 10. (Original) The method of claim 1, wherein the nucleic acid does not encode a protein having antiangiogenesis activity.
- 11. (Original) The method of claim 1, wherein the nucleic acid has a modified backbone.
- 12. (Original) The method of claim 11, wherein the modified backbone is a phosphate backbone modification.
- 13. (Original) The method of claim 11, wherein the modified backbone is a peptide modified oligonucleotide backbone.
- 14. (Original) The method of claim 1, further comprising administering to the subject at least one anticancer agent.
- 15. (Original) The method of claim 1, further comprising administering to the subject at least one antiarthritis agent.
- 16. (Original) The method of claim 6, wherein the CpG nucleic acid comprises: $5' \ X_1 \ X_2 CG X_3 \ X_4 \ 3'$

wherein C is unmethylated, and wherein X_1X_2 and X_3X_4 are nucleotides.

BEST AVAILABLE COPY

- 17. (Original) The method of claim 16, wherein the 5' X_1 X_2 CG X_3 X_4 3' sequence is a non-palindromic sequence.
- 18. (Original) The method of claim 16, wherein the CpG nucleic acid has 8 to 100 nucleotides.
 - 53.–74. (Cancelled)